AU2004275881A1 - 9,10-alpha,alpha-OH-taxane analogs and methods for production thereof - Google Patents

9,10-alpha,alpha-OH-taxane analogs and methods for production thereof Download PDF

Info

Publication number
AU2004275881A1
AU2004275881A1 AU2004275881A AU2004275881A AU2004275881A1 AU 2004275881 A1 AU2004275881 A1 AU 2004275881A1 AU 2004275881 A AU2004275881 A AU 2004275881A AU 2004275881 A AU2004275881 A AU 2004275881A AU 2004275881 A1 AU2004275881 A1 AU 2004275881A1
Authority
AU
Australia
Prior art keywords
group
formula
ocoph
coo
olefinic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2004275881A
Other languages
English (en)
Inventor
James Ferrara
James D. Mcchesney
Jan Zygmut
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tapestry Pharmaceuticals Inc
Original Assignee
Tapestry Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tapestry Pharmaceuticals Inc filed Critical Tapestry Pharmaceuticals Inc
Publication of AU2004275881A1 publication Critical patent/AU2004275881A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2004275881A 2003-09-25 2004-09-27 9,10-alpha,alpha-OH-taxane analogs and methods for production thereof Abandoned AU2004275881A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US50668003P 2003-09-25 2003-09-25
US60/506,680 2003-09-25
PCT/US2004/031816 WO2005030150A2 (en) 2003-09-25 2004-09-27 9,10-α,α-OH-TAXANE ANALOGS AND METHODS FOR PRODUCTION THEREOF

Publications (1)

Publication Number Publication Date
AU2004275881A1 true AU2004275881A1 (en) 2005-04-07

Family

ID=34393186

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004275881A Abandoned AU2004275881A1 (en) 2003-09-25 2004-09-27 9,10-alpha,alpha-OH-taxane analogs and methods for production thereof

Country Status (14)

Country Link
US (8) US7745650B2 (enExample)
EP (2) EP1664033B1 (enExample)
JP (5) JP4874102B2 (enExample)
CN (1) CN1886400A (enExample)
AT (1) ATE377593T1 (enExample)
AU (1) AU2004275881A1 (enExample)
CA (1) CA2539975C (enExample)
DE (1) DE602004009943T2 (enExample)
DK (1) DK1664033T3 (enExample)
ES (1) ES2295937T3 (enExample)
HR (1) HRP20080057T3 (enExample)
PL (1) PL1664033T3 (enExample)
PT (1) PT1664033E (enExample)
WO (1) WO2005030150A2 (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1664033B1 (en) 2003-09-25 2007-11-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof
US7754850B2 (en) 2005-02-11 2010-07-13 University Of Southern California Chimeric disintegrin domain
WO2007073383A1 (en) * 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
JP2009521463A (ja) * 2005-12-21 2009-06-04 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体のための方法およびそれに有用な中間体
JP2009531446A (ja) * 2006-03-27 2009-09-03 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体の合成のためのコンバージェントプロセス
US8008256B2 (en) * 2006-05-01 2011-08-30 University Of Southern California Combination therapy for treatment of cancer
US7847111B2 (en) 2006-06-19 2010-12-07 Canada Inc. Semi-synthetic route for the preparation of paclitaxel, docetaxel, and 10-deacetylbaccatin III from 9-dihydro-13-acetylbaccatin III
EP2029563A4 (en) * 2006-06-12 2009-12-02 Canada Inc 6570763 HALF-SYNTHETIC ROUTE FOR THE PREPARATION OF PACLITAXEL, DOCETAXEL AND 10-DEACETYLBACCATIN III FROM 9-DIHYDRO-13-ACETYLBACCATIN III
US11786504B2 (en) 2006-09-28 2023-10-17 Tapestry Pharmaceuticals, Inc. Taxane analogs for the treatment of brain cancer
US11873308B2 (en) 2006-11-06 2024-01-16 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US20080207743A1 (en) * 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment
WO2010056901A2 (en) 2008-11-13 2010-05-20 University Of Southern California Method of expressing proteins with disulfide bridges with enhanced yields and activity
US9227983B2 (en) 2011-04-07 2016-01-05 Arbor Therapeutics, LLC Taxane and abeo-taxane analogs
KR20140048113A (ko) * 2011-04-07 2014-04-23 아버 테라퓨틱스 엘엘씨 탁산 및 아베오-탁산 유사체
AU2012275953B2 (en) * 2011-06-06 2015-01-22 Arbor Therapeutics, LLC Acid-labile lipophilic prodrugs of cancer chemotherapeutic agents
DK4096588T3 (da) 2020-03-04 2024-10-21 Aquedeon Medical Inc Instrument til anlæggelse af en vaskulær og aortatransplantat konnektor med teleskopskede

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
US6794523B2 (en) * 1991-09-23 2004-09-21 Florida State University Taxanes having t-butoxycarbonyl substituted side-chains and pharmaceutical compositions containing them
DK0639186T3 (da) * 1992-04-17 1999-12-13 Abbott Lab Taxolderivater
FR2697019B1 (fr) * 1992-10-15 1994-11-25 Rhone Poulenc Rorer Sa Nouveaux dérivés du taxane, leur préparation et les compositions pharmaceutiques qui les contiennent.
JPH08503218A (ja) * 1992-11-13 1996-04-09 フロリダ・ステート・ユニバーシティー ブテニル置換タキサンおよび組成物
US6066747A (en) * 1993-03-05 2000-05-23 Florida State University Process for the preparation of 9-desoxotaxanes
US6710191B2 (en) * 1993-03-05 2004-03-23 Florida State University 9β-hydroxytetracyclic taxanes
DE69430797T2 (de) 1993-03-05 2003-02-27 Florida State University, Tallahassee C9 taxanderivate und diese enthaltende pharmazeutische zusammensetzungen
ATE295164T1 (de) * 1993-03-22 2005-05-15 Univ Florida State Taxane mit furyl oder thienyl enthaltender substituierter seitenkette
FR2707293A1 (fr) 1993-07-08 1995-01-13 Rhone Poulenc Rorer Sa Nouveaux taxoides, leur préparation et les compositions pharmaceutiques qui les contiennent.
FR2715846A1 (fr) * 1994-02-07 1995-08-11 Rhone Poulenc Rorer Sa Nouvelle composition pharmceutique à base de taxoïdes.
IT1275936B1 (it) 1995-03-17 1997-10-24 Indena Spa Derivati della 10-deacetilbaccatina iii e della 10-deacetil-14b- idrossibaccatina iii loro metodo di preparazione e formulazioni
US5635531A (en) * 1996-07-08 1997-06-03 Bristol-Myers Squibb Company 3'-aminocarbonyloxy paclitaxels
US5739359A (en) 1997-01-24 1998-04-14 Virginia Tech Intellectual Properties, Inc. Methods for preparing 1-deoxy paclitaxels
US6048990A (en) * 1998-05-01 2000-04-11 Napro Biotherapeutics, Inc. Method for selective acylation of C-2'-O-protected-10-hydroxy-taxol at the C-10 position
CO5280224A1 (es) * 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
HK1047896A1 (zh) 2000-02-02 2003-03-14 佛罗里达州立大学研究基金有限公司 C10杂取代的乙酸基紫衫烷抗肿瘤剂
JP2004528309A (ja) 2001-03-23 2004-09-16 ナプロ バイオセラピューティクス，インコーポレイテッド 癌治療用分子複合体
CA2354471A1 (en) 2001-07-31 2003-01-31 Florida State University Research Foundation, Inc. C10 ester substituted taxanes
AU2002361701A1 (en) 2001-12-20 2003-07-09 Bristol-Myers Squibb Company Pharmaceutical compositons of orally active taxane derivatives having enhanced bioavailability
US6898834B1 (en) * 2003-03-03 2005-05-31 Westbridge Pty Ltd Barrel stave reclaim
EP1894921A3 (en) 2003-09-25 2008-03-12 Tapestry Pharmaceuticals, Inc. 9, 10-Alpha, Alpha-Oh-Taxane analogs and methods for production thereof
EP1664033B1 (en) * 2003-09-25 2007-11-07 Tapestry Pharmaceuticals, Inc. 9,10-alpha,alpha-oh-taxane analogs and methods for production the reof
AU2006247471A1 (en) 2005-05-12 2006-11-23 Tapestry Pharmaceuticals, Inc. Molecular constructs suitable for targeted conjugates
WO2007073383A1 (en) 2005-12-21 2007-06-28 Tapestry Pharmaceuticals, Inc. Novel compounds and methods for forming taxanes and using the same
JP2009521463A (ja) 2005-12-21 2009-06-04 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体のための方法およびそれに有用な中間体
JP2009531446A (ja) 2006-03-27 2009-09-03 タペストリー ファーマシューティカルズ インコーポレーテッド タキサン誘導体の合成のためのコンバージェントプロセス
WO2008121476A1 (en) 2007-03-28 2008-10-09 Tapestry Pharmaceuticals, Inc. Biologically active taxane analogs and methods of treatment by oral administration
WO2008109360A1 (en) 2007-02-28 2008-09-12 Tapestry Pharmaceuticals, Inc Taxane analogs for the treatment of brain cancer
US20080207743A1 (en) 2007-02-28 2008-08-28 Rodger Lamb Biologically Active Taxane Analogs and Methods of Treatment

Also Published As

Publication number Publication date
US8962870B2 (en) 2015-02-24
US20160331718A1 (en) 2016-11-17
US20180125811A1 (en) 2018-05-10
JP2007506792A (ja) 2007-03-22
JP2011012070A (ja) 2011-01-20
US20100324128A1 (en) 2010-12-23
JP6216417B2 (ja) 2017-10-18
EP1664033A2 (en) 2006-06-07
US20120077871A1 (en) 2012-03-29
ES2295937T3 (es) 2008-04-16
EP1785416A2 (en) 2007-05-16
PL1664033T3 (pl) 2008-04-30
JP2014196345A (ja) 2014-10-16
JP6106634B2 (ja) 2017-04-05
US20150133536A1 (en) 2015-05-14
JP4874102B2 (ja) 2012-02-15
US20190142784A1 (en) 2019-05-16
US20200237708A1 (en) 2020-07-30
JP5629632B2 (ja) 2014-11-26
US9820962B2 (en) 2017-11-21
JP2011137045A (ja) 2011-07-14
US10639293B2 (en) 2020-05-05
ATE377593T1 (de) 2007-11-15
CA2539975C (en) 2012-11-20
EP1785416A3 (en) 2007-05-30
JP2016180006A (ja) 2016-10-13
EP1664033A4 (en) 2006-09-13
JP5525394B2 (ja) 2014-06-18
CA2539975A1 (en) 2005-04-07
DK1664033T3 (da) 2008-03-25
DE602004009943T2 (de) 2008-08-28
US10238621B2 (en) 2019-03-26
US9402824B2 (en) 2016-08-02
EP1664033B1 (en) 2007-11-07
CN1886400A (zh) 2006-12-27
US7879904B2 (en) 2011-02-01
WO2005030150A2 (en) 2005-04-07
HRP20080057T3 (en) 2008-02-29
WO2005030150A3 (en) 2005-07-14
DE602004009943D1 (de) 2007-12-20
US7745650B2 (en) 2010-06-29
US20050148657A1 (en) 2005-07-07
PT1664033E (pt) 2008-01-17

Similar Documents

Publication Publication Date Title
US10639293B2 (en) 9,10-α,α-OH-taxane analogs and methods for production thereof
SI9520078A (en) Semi-synthetic taxanes with anti-tumoural activity
US20110028539A1 (en) Biologically active taxane analogs and methods of treatment
EP1810968A2 (en) 9, 10-a, a-OH-texane analogs and methods for production thereof
AU2002234535A1 (en) A process for the preparation of paclitaxel
EP1339703A1 (en) A process for the preparation of paclitaxel
JPH08505856A (ja) １０−デスアセトキシバッカチン▲ｉｉｉ▼の製法
CN103012330A (zh) 一种紫杉醇类抗癌药xrp6258的制备方法
KR101379694B1 (ko) 탁산유도체의 제조방법
JPH0570636B2 (enExample)
AU2007341070A1 (en) A process for the preparation of secotaxanes

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application